Lazard Asset Management
STOK icon

Lazard Asset Management’s Stoke Therapeutics STOK Stock Holding History

Lazard Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13,832
Closed -$156K – 2285
2025
Q2 		$156K Buy
+13,832
New +$131K ﹤0.01% 1759
2025
Q1 		– Sell
-58
Closed – – 2571
2024
Q4 		$0 Hold
58
– – ﹤0.01% 2527
2024
Q3 		$0 Sell
58
-155
-73% -$2.2K ﹤0.01% 2447
2024
Q2 		$2K Sell
213
-3,497
-94% -$47.2K ﹤0.01% 2112
2024
Q1 		$49K Sell
3,710
-2,069
-36% -$12.5K ﹤0.01% 1718
2023
Q4 		$29K Buy
5,779
+222
+4% +$949 ﹤0.01% 2018
2023
Q3 		$21K Buy
5,557
+2,723
+96% +$17.9K ﹤0.01% 2090
2023
Q2 		$29K Buy
2,834
+930
+49% +$9.89K ﹤0.01% 2015
2023
Q1 		$15K Buy
1,904
+407
+27% +$3.67K ﹤0.01% 2097
2022
Q4 		$13K Buy
+1,497
New +$15.6K ﹤0.01% 2180

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

Lazard Asset Management's STOK Position: Q3 2025 in Review

Lazard Asset Management sold out of Stoke Therapeutics (STOK) in Q3 2025, closing a stake of 13,832 shares — an estimated $156K sold.

Lazard Asset Management first reported a position in STOK in Q4 2022 and held it in 10 quarters. The position peaked at $156K in Q2 2025. 151 funds tracked by Wall St. Rank hold STOK as of Q3 2025.

  • Lazard Asset Management reported no remaining Stoke Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Lazard Asset Management sold 13,832 Stoke Therapeutics shares in Q3 2025, an estimated $156K.
  • Lazard Asset Management first reported a position in Stoke Therapeutics in Q4 2022 and held it in 10 quarters.
  • Lazard Asset Management's Stoke Therapeutics position peaked at $156K in Q2 2025.
  • 151 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2025.

Based on Lazard Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.